Scientists defined the role of NF1 deficiency in estrogen receptor (ER)-positive breast cancer metabolic reprogramming and identified potential targeted pathway and metabolic inhibitor combination therapies for NF1-deficient ER + breast cancer.
[Molecular Metabolism]
